Chen Jinbo, Yang Xiong, Gong Dongkui, Cui Yu, Hu Jiao, Li Huihuang, Liu Peihua, Li Chao, Cheng Xu, Liu Longfei, Chen Hequn, Zu Xiongbing
Department of Urology, Xiangya Hospital, Central South University, Changsha.
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Medicine (Baltimore). 2019 Jan;98(3):e14095. doi: 10.1097/MD.0000000000014095.
BACKGROUND/AIMS: Emerging evidence showed the long noncoding RNA X-inactive specific transcript (lncRNA XIST) may play a crucial role in various cancers. However, its prognostic value in cancer patients remains controversial. Therefore, we performed an in-depth meta-analysis to investigate the potential clinical value of lncRNA XIST as a prognostic marker for cancer patients.
A comprehensive literature search was performed from PubMed, Embase and the Cochrane Central Search Library by January 2018. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% Cl) were calculated to evaluate the prognosis as well as clinicopathological parameters of XIST, respectively.
A total of 18 retrospective studies with 1351 cancer patients were included. Current meta-analysis revealed that elevated lncRNA XIST expression was associated with poor overall survival (OS) (HR = 2.14, 95% CI = 1.26-3.64; P = .005) and disease free survival (DFS) (HR = 4.52, 95% CI = 1.42-14.37; P = .011). The clinicopathological parameters analysis demonstrated that increased XIST expression was significantly associated with tumor size (OR = 2.93, 95% CI = 2.24-3.84; P < .001), clinical stage (OR = 2.73, 95% CI = 1.62-4.58; P < .001) and lymph node metastasis (OR = 2.44, 95% CI = 1.74-3.42; P < .001). In addition, subgroup analysis based on cancer type revealed that lncRNA XIST expression correlated with distant metastasis in digestive cancer (OR = 2.90, 95% CI = 1.80-4.68; P < .001).
The current meta-analysis results indicated lncRNA XIST expression level could serve as a prognostic predictor and biomarker in multiple cancers.
背景/目的：新出现的证据表明，长链非编码RNA X染色体失活特异性转录本（lncRNA XIST）可能在多种癌症中发挥关键作用。然而，其在癌症患者中的预后价值仍存在争议。因此，我们进行了一项深入的荟萃分析，以研究lncRNA XIST作为癌症患者预后标志物的潜在临床价值。
截至2018年1月，通过PubMed、Embase和Cochrane中心检索库进行了全面的文献检索。分别计算合并风险比（HRs）或比值比（ORs）及95%置信区间（95% Cl），以评估XIST的预后及临床病理参数。
共纳入18项涉及1351例癌症患者的回顾性研究。当前的荟萃分析显示，lncRNA XIST表达升高与总生存期（OS）较差相关（HR = 2.14，95% CI = 1.26 - 3.64；P = 0.005）及无病生存期（DFS）较差相关（HR = 4.52，95% CI = 1.42 - 14.37；P = 0.011）。临床病理参数分析表明，XIST表达增加与肿瘤大小（OR = 2.93，95% CI = 2.24 - 3.84；P < 0.001）、临床分期（OR = 2.73，95% CI = 1.62 - 4.58；P < 0.001）及淋巴结转移（OR = 2.44，95% CI = 1.74 - 3.42；P < 0.001）显著相关。此外，基于癌症类型的亚组分析显示，lncRNA XIST表达与消化道癌症的远处转移相关（OR = 2.90，95% CI = 1.80 - 4.68；P < 0.001）。
当前的荟萃分析结果表明，lncRNA XIST表达水平可作为多种癌症的预后预测指标和生物标志物。
